Identification of Anti-Long Chain Saturated Fatty Acid IgG Antibodies in Serum of Patients with Type 2 Diabetes

Figure 5

Detection of anti-LCSFA antibodies in human serum. (a) Anti-LCSFA IgG in serum of Hispanic En Balance participants with type 2 diabetes is reduced following 3 months of diabetes education. Each data point represents the mean optical density of anti-LCSFA IgG antibodies detectable by ELISA. The cut-off value for positive antibody reactivity against BSA-PA (>0.186) was defined as an absorbance greater than two standard deviations above the mean value for BSA. The frequency of sera positive for each group is indicated as a percent on the graph. (b) Paired data from the 21 En Balance participants with both baseline (mean ± SEM = ) and 3-month serum (mean ± SEM = ) samples. The black lines connect data points belonging to the same participant. Data was analyzed by Mann-Whitney (for (a)) and Wilcoxon test (for (b)). (c) Frequency of anti-LCSFA IgG Abs in serum samples from Bioserve biorepository. CC: Caucasian control; CD: Caucasian diabetic; HC: Hispanic control; HD: Hispanic diabetic. The cut-off value for positive antibody reactivity against BSA-PA (>0.166) was defined as an absorbance greater than two standard deviations above the mean value for BSA. (d) Comparison of anti-LCSFA IgG levels among En Balance serum samples and Bioserve biorepository serum samples. The median of all corrected OD values (OD₄₅₀ of BSA-PA reactivity − OD₄₅₀ of BSA reactivity) for each sample was determined. The corrected OD value for each sample was divided by the median to obtain the Multiple of the Median (MoM). A MoM value of 1 is considered the “normal” range for the anti-LCSFA antibody. BL: En Balance baseline samples; 3 Mo: En Balance 3-month samples. Data was analyzed by Mann-Whitney. .

(a)

(b)

(c)

(d)